静脉血栓栓塞症诊治的最新关注

doi:10.16139/j.1007-9610.2019.01.003

摘要/Abstract

中图分类号:

R654.3

张福先. 静脉血栓栓塞症诊治的最新关注[J]. 外科理论与实践, 2019, 24(04): 293-296.

[1] Deitelzweig SB, Johnson BH, Lin J, et al.Prevalence of clinical venous thromboembolism in the USA: current trends and future projections[J]. Am J Hematol,2011,86(2):217-220.
[2] Huang D, Chan PH, She HL, et al.Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016[J]. Thromb Res,2018,166:80-85.
[3] 张福先. 肢体深静脉血栓形成与肺动脉栓塞发生关系的探讨[J]. 中华结核和呼吸杂志,2000,9(23):531-533
[4] Roger VL, Go AS, Lloyd-Jones DM, et al.Heart disease and stroke statistics--2011 update: a report from the American Heart Association[J]. Circulation,2011,123(4):e18-e209.
[5] Dalen JE, Alpert JS.Natural history of pulmonary embolism[J]. Prog Cardiovas Dis,1975,17(4):259-270.
[6] Feng Y, Zhang F, Niu L, et al.Simvastatin ameliorates deep vein thrombosis in rabbits by regulating the fibrinolytic system[J]. Blood Coagul Fibrinolysis,2016,27(5):531-541.
[7] O'Connor P, Lookstein R. Endovascular Interventions for venous disease[J]. Tech Vasc Interv Radiol,2018,21(2):55-64.
[8] Collins R, Scrimgeour A, Yusuf S, et al.Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopaedic, and urologic surgery[J]. N Engl J Med,1988, 318(18):1162-1173.
[9] Masuda EM, Kessler DM, Kistner RL, et al.The natural history of calf vein thrombosis: lysis of thrombi and development of reflux[J]. J Vasc Surg,1998,28(1):67-74.
[10] Kahn SR, Shbaklo H, Lamping DL, et al.Determinants of health- related quality of life during the 2 years following deep vein thrombosis[J]. J Thromb Haemost,2008,6(7):1105-1112
[11] Garcia MJ, Lookstein R, Malhotra R, et al.Endovascular management of deep vein thrombosis with rheolytic thrombectomy: final report of the prospective multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) registry[J]. J Vasc Interv Radiol,2015,26(6):777-785.
[12] Geerts WH, Bergqvist D, Pineo GF, et al.Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest,2008,133(6 Suppl):381S-453S.
[13] Agnelli G, Bolis G, Capussotti L, et al.A clinical outcome-based prospective study on venous thromboembolism after cance surgery: the @RISTOS project[J]. Ann Surg,2006,243(1):89-95.
[14] 罗小云, 张福先, 张昌明, 等. 以下肢深静脉血栓形成为最初临床表现的恶性肿瘤病例分析[J]. 中华普通外科杂志,2013,28(12):931-933
[15] Timp JF, Braekkan SK, Versteeg HH, et al.Epidemiology of cancer-associated venous thrombosis[J]. Blood,2013, 122(10):1712-1723.
[16] Blom JW, Doggen CJ, Osanto S, et al.Malignancies, prothrombotic mutations, and the risk of venous thrombosis[J]. JAMA,2005,293(6):715-722.
[17] Guo Q, Huang B, Zhao J, et al.Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis[J]. Ann Surg,2017,265(6):1087-1093.
[18] Fagarasanu A, Alotaibi GS, Hrimiuc R, et al.Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis[J]. Ann Surg Oncol,2016,23(5):1422-1430.
[19] Khorana AA, Carrier M, Garcia DA, et al.Guidance for the prevention and treatment of cancer-associated venous thromboembolism[J]. J Thromb Thrombolysis,2016,41(1):81-91.
[20] Wang TF, Li A, Garcia D.Managing thrombosis in cancer patients[J]. Res Pract Thromb Haemost,2018,2(3):429-438.
[21] Young AM, Marshall A, Thirlwall J, et al.Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial(SELECT-D)[J]. J Clin Oncol,2018,36(20):2017-2023.
[22] Khorana AA, Vadhan-Raj S, Kuderer NM, et al.Rivaro-xaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial[J]. Thromb Haemost,2017,117(11):2135-2145.
[23] Godin R, Roy G, Douketis J.An opinion on the benefits of concomitant oral contraceptive therapy in premenopausal women treated with oral anticoagulants[J]. Thromb Res,2018,165:14-17.
[24] Salibaa W, WarwarcA, Kotlerc A, et al. Association of factor Ⅴ activity with risk of venous thromboembolism and atherothrombotic cardiovascular events: A retrospective population-based cohort study[J]. Thromb Res,2018, 168:14-19.
[25] Maufus M, Elias A, Barrellier MT, et al.Diagnosis of deep vein thrombosis recurrence: Ultrasound criteria[J]. Thromb Res,2018,161:78-83.

静脉血栓栓塞症诊治的最新关注

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张伯玮, 任静, 马睿, 门剑龙. D-二聚体在静脉血栓栓塞症诊疗中的应用临床实践[J]. 诊断学理论与实践, 2020, 19(05): 469-473.
[2]	毛毅敏, 黄伸伸, 和雪改. 围手术期静脉血栓栓塞症形成风险评估及抗凝药物管理[J]. 诊断学理论与实践, 2019, 18(1): 16-20.
[3]	门剑龙, 任静. 静脉血栓栓塞症的危险因素和危险分层诊断[J]. 诊断学理论与实践, 2019, 18(1): 10-15.
[4]	李健, 武彪. 腹股沟疝术后下肢深静脉血栓形成的治疗体会[J]. 外科理论与实践, 2018, 23(05): 437-439.
[5]	吴炳祥, 孙娜,. 新型口服抗凝药物在静脉血栓栓塞症预防和治疗方面的应用进展[J]. 内科理论与实践, 2014, 9(04): 251-255.
[6]	丁永杰, 时国朝, 李敏,. 肿瘤相关静脉血栓栓塞症预防现状[J]. 内科理论与实践, 2012, 7(01): 56-59.
[7]	蒋米尔, 殷敏毅,. 静脉血栓栓塞症的诊断现状[J]. 诊断学理论与实践, 2011, 10(02): 93-96.
[8]	区满春, 曾敏怡, 石任任, 陈靖, 方劭桦, 谢玮, 冯莹,. 静脉血栓栓塞症高危因素和临床表现的荟萃分析[J]. 诊断学理论与实践, 2011, 10(02): 113-116.
[9]	黎成金, 焦占江, 王冰, 王烈,. 急性下肢深静脉血栓形成综合治疗的临床分析[J]. 外科理论与实践, 2010, 15(04): 445-446.
[10]	严赟琦, 张皓,. 下肢深静脉血栓形成综合征的诊断及治疗[J]. 外科理论与实践, 2010, 15(03): 321-324.
[11]	王项潮, 王璞,. Aegisy可回收腔静脉滤器在创伤外科的临床应用[J]. 外科理论与实践, 2010, 15(03): 283-285.
[12]	徐琳, 吴性江, 范欣馨, 潘争妍,. 导管介入溶栓治疗下肢深静脉血栓形成不同给药方式的疗效分析[J]. 外科理论与实践, 2009, 14(05): 534-537.
[13]	徐希奇, 蒋鑫, 何晶, 赵勤华, 马传荣, 荆志成,. 国产低分子量肝素治疗静脉血栓栓塞症的有效性和安全性研究[J]. 内科理论与实践, 2008, 3(06): 431-432.
[14]	王嫱, 龚朱, 梁爱斌, 汪浩, 沈玉琴, 王乐民,. 静脉血栓栓塞症患者血小板相关因子mRNA显著性差异表达的意义[J]. 内科理论与实践, 2008, 3(06): 423-427.
[15]	王兆钺,. 血栓病的诊断指南解读[J]. 诊断学理论与实践, 2008, 7(05): 570-573.